Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances. We do not ...

A triple dose of Novo Nordisk's GLP-1 agonist Wegovy has shown improved activity on weight loss in an obesity trial, as the drugmaker tries to fend off a marketplace challenge from Eli Lilly. A 7.2mg ...

Mark Leiser is Healio's Oncology Insider, providing insightful analysis of therapeutic advances, clinical innovations, practice challenges and emerging trends that are shaping cancer care. With more ...